Marshall Wace
LYEL icon

Marshall Wace’s Lyell Immunopharma LYEL Stock Holding History

Marshall Wace’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Sell
106,300
-42,216
-28% -$764K ﹤0.01% 2006
2026
Q1 		$2.98M Buy
148,516
+75,201
+103% +$1.76M ﹤0.01% 1570
2025
Q4 		$2.26M Buy
+73,315
New +$1.64M ﹤0.01% 1520
2025
Q3 		– Sell
-10,580
Closed -$93.5K – 3182
2025
Q2 		$93.5K Buy
+10,580
New +$96.4K ﹤0.01% 2550

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Marshall Wace's LYEL Position: Q2 2026 in Review

Marshall Wace reduced its Lyell Immunopharma (LYEL) stake by 28% in Q2 2026, selling an estimated $764K and leaving 106,300 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2006.

Marshall Wace first reported a position in LYEL in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.98M in Q1 2026. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Marshall Wace held 106,300 shares of Lyell Immunopharma worth $1.49M as of Q2 2026.
  • Marshall Wace sold 42,216 Lyell Immunopharma shares in Q2 2026, an estimated $764K.
  • Lyell Immunopharma made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2006 holding.
  • Marshall Wace first reported a position in Lyell Immunopharma in Q2 2025 and has held it in 4 quarters since.
  • Marshall Wace's Lyell Immunopharma position peaked at $2.98M in Q1 2026.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.